AUS
NZ
UK
CA
USA
IND
Highlights
- Paragon Care remains on track to achieve its 3-2-1 Strategy goals by the end of FY26.
- The company recorded a 21.7% YoY revenue increase to AUD 3.61 billion for FY25, with EBIT more than doubling to AUD 58.6 million.
- The company appointed Brendon Pentland as CFO, bringing over 25 years of finance experience to support growth and restructuring efforts.
- Paragon Care’s Singapore subsidiary signed an AUD 70 million binding agreement to acquire PT Haju Medical Indonesia and Insightof Co., Ltd.
Paragon Care Limited (ASX:PGC), a prominent Australian healthcare supplier specialising in medical equipment, consumables, and pharmaceuticals, has confirmed that its transition towards delivering its 3-2-1 (three team, two years, one team) strategy remains on course for completion by the end of the 2026 fiscal year.
Financial Growth Driven by Strategic Acquisitions and Integration
For the full year ending 30 June 2025 (FY25), the company reported revenue growth of 21.7% YoY, reaching AUD 3.61 billion. Meanwhile, earnings before interest and tax (EBIT) more than doubled to AUD 58.6 million, an increase of 105.6% YoY, and profit before tax surged by 84.8% YoY to AUD 25.5 million. Yearly revenue growth was driven by expansion in ANZ wholesale operations, new contract wins in medical technology, contract logistics growth, and the ramp-up of clinical manufacturing activities.
The year’s EBITDA almost doubled, supported by integration benefits from acquisitions including CH2, Oborne, and ParagonCare. Despite some impacts from higher inventory levels and delayed debt recovery, organic growth and acquisitions helped support earnings performance.
New CFO Appointment and Major Acquisition
Recently, the company appointed Brendon Pentland as its Chief Financial Officer. With over 25 years of international finance experience, Pentland’s expertise will support strategic investments, acquisitions, and financial restructuring, helping to guide the company’s future growth in the Asia-Pacific region.
Through an ASX update dated 1 December 2025, the company informed that its Singapore subsidiary signed a binding agreement to acquire PT Haju Medical Indonesia and Insightof Co., Ltd for AUD 70 million. This acquisition will expand the company’s presence in the medical aesthetics market across Southeast Asia and is expected to be earnings accretive in FY26. Funding will come through working capital facilities and surplus cash, as noted by the company.
Outlook
Looking ahead, the company projects underlying revenue for FY26 to range between AUD 3.6 billion and AUD 3.7 billion, driven by ongoing ANZ growth, Asian expansion, and new business units. Underlying EBITDA is forecasted between AUD 97.5 million and AUD 107.5 million, supported by integration benefits, operational efficiencies, and contributions from recent M&A activities.
Full integration of merged businesses is projected to be completed by the end of FY26, delivering streamlined operations and improved ERP systems across ANZ and Asia-Pacific. Expansion in aesthetics, robotics, and dental sectors through new contracts and agency acquisitions is expected to continue.
Share Performance of PGC
PGC shares remained flat at AUD 0.240 per share on 10 December 2025. The stock has experienced a decline of 51.99% over the past year and has fallen 39.99% over both the past six and nine months. In the last three months, the share price dropped by 26.15%, while it decreased by 22.58% over the past month. The 52-week high for PGC is AUD 0.590, recorded on 3 February 2025, and the 52-week low is AUD 0.230, reached on 9 December 2025.
Support and Resistance Summary
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 10 December 2025. The reference data in this report has been partly sourced from EODHD/Others.
Technical Indicators Defined:
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.
